Halozyme Provides 2023 Financial Guidance and Outlook
2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue
2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $455 Million
2023 EBITDA Projected to Grow by >30% Year-Over-Year to $415 to $440 Million
2023 Non-GAAP Diluted EPS Guidance of $2.50 to $2.65
SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced its 2023 financial guidance and commented on its outlook for the upcoming year.
"In 2022, we project we achieved record revenue of greater than $655 million and we completed the acquisition of Antares Pharma, opening up an expanded set of opportunities for our subcutaneous dru
